AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 17:57:29 28/05/2026 BST			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	44.65M 50.96M 41.45M 38.09M 71.77M 4.92B 72.83M 494M 193M 2.41B 191M 187M 8.31B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	44.65M 50.96M 41.45M 38.09M 71.77M 4.92B 72.83M 494M 193M 2.41B 191M 187M 8.31B	EV / Sales 2026 *	37.2x	EV / Sales 2027 *	34.3x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-06	AB Science S.A. Announces Board Changes	CI
07-06	AB Science S.A. Announces CEO Changes	CI
07-02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib

07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-13	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
07-13	Wall Street ne chômera pas le 14 juillet
07-10	AB Science rationalise son portefeuille et se recentre sur deux molécules
07-10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	4.46
5 years	0	18.78
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	06/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	19/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	31/03/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	10/07/2001
Patrick Moussy BRD	Director/Board Member	-	19/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	26/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	50.96M
MERCK & CO., INC.	+1.91%	+1.57%	+54.36%	+19.16%	315B
MERCK KGAA	+1.77%	+1.12%	+24.22%	-11.46%	67.93B
HALOZYME THERAPEUTICS, INC.	+1.36%	+1.43%	+34.31%	+83.93%	9.23B
KYOWA KIRIN CO., LTD.	-1.26%	-1.95%	+2.83%	-4.98%	8.43B
SK BIOPHARMACEUTICALS CO., LTD.	-1.03%	-1.79%	-24.11%	-10.07%	4.07B
BETTA PHARMACEUTICALS CO., LTD.	+0.38%	-9.58%	-5.58%	+22.13%	3.77B
YUHAN CORPORATION	+0.86%	+1.01%	-43.84%	+10.01%	3.54B
SUPERNUS PHARMACEUTICALS, INC.	-0.61%	-3.07%	+41.73%	+55.51%	2.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.81%	-6.33%	+5.13%	-9.94%	2.13B
Average	+0.07%	-0.91%	+9.89%	+17.14%	46.3B
Weighted average by Cap.	+1.74%	+3.04%	+45.48%	+14.86%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.93M 132M 1.96M 13.27M 5.19M 64.67M 5.14M 5.03M 223M	1.3M 1.48M 1.21M 1.11M 2.09M 143M 2.12M 14.38M 5.63M 70.05M 5.57M 5.45M 242M
Net income	-	-
Net Debt	-	-